Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022047243 - METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER

Publication Number WO/2022/047243
Publication Date 03.03.2022
International Application No. PCT/US2021/048074
International Filing Date 27.08.2021
IPC
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/18 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/32 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products from oncogenes
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/2878
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2878against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 16/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products of oncogenes
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
Applicants
  • ENOSI LIFE SCIENCES CORP. [US]/[US]
Inventors
  • SHEPARD, Harold, Michael
Agents
  • SEIDMAN, Stephanie, L.
  • MISKIEL, Frank, J.
Priority Data
63/071,31327.08.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER
(FR) MÉTHODES ET COMPOSITIONS POUR TRAITER DES MALADIES AUTO-IMMUNES ET UN CANCER
Abstract
(EN) Provided are molecular constructs that target tumor necrosis factor receptor 1 (TNFR1) and/or tumor necrosis factor receptor 2 (TNFR2). The constructs are for treating diseases, disorders, and conditions in which these receptors and/or TNF are involved in the etiology or in which their inhibition or activation thereof can ameliorate the disease, disorder, and condition or a symptom thereof. Among the constructs provided herein, are TNFR1 antagonist constructs that are engineered to inhibit TNFR1 function, and to eliminate any TNFR1 agonist activity. The constructs provided herein include agonists and antagonists of TNFR1 and TNFR2. TNFR1 antagonist constructs are engineered to inhibit TNFR1 function, and in some embodiments, are engineered to avoid agonist activity. Included also are agonists and antagonists of TNFR2. Agonists of TNFR2 increase regulatory T-cell function to control acute or chronic inflammation. Antagonists of TNFR2 decrease regulatory T- cell function thus increasing immunity, and are for treating cancer and certain immunodeficiency diseases. Methods of treatment of the various diseases in which TNF and its receptors play a role also are provided.
(FR) L'invention concerne des constructions moléculaires ciblant le récepteur 1 du facteur de nécrose tumorale (TNFR1) et/ou le récepteur 2 du facteur de nécrose tumorale (TNFR2). Les constructions sont destinées au traitement de maladies, de troubles et d'états dans lesquels ces récepteurs et/ou TNF sont impliqués dans l'étiologie ou dans lesquels leur inhibition ou leur activation peut améliorer la maladie, le trouble, et l'état ou un symptôme associé. Parmi les constructions fournies dans l'invention, se trouvent des constructions antagonistes de TNFR1 qui sont conçues pour inhiber la fonction de TNFR1, et pour éliminer toute activité agoniste de TNFR1. Les constructions de l'invention comprennent des agonistes et des antagonistes de TNFR1 et TNFR2. Des constructions antagonistes de TNFR1 sont conçues pour inhiber la fonction de TNFR1, et dans certains modes de réalisation, sont conçues pour éviter une activité agoniste. L'invention concerne également des agonistes et des antagonistes de TNFR2. Les agonistes de TNFR2 augmentent la fonction des lymphocytes T régulateurs pour contrôler une inflammation aiguë ou chronique. Les antagonistes de TNFR2 diminuent la fonction des lymphocytes T régulateurs augmentant ainsi l'immunité, et sont destinés au traitement du cancer et de certaines maladies d'immunodéficience. L'invention concerne également des méthodes de traitement des diverses maladies dans lesquelles le TNF et ses récepteurs jouent un rôle.
Latest bibliographic data on file with the International Bureau